These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 27321025)

  • 1. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
    Basu S; Alavi A
    PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors.
    Basu S; Ranade R; Ostwal V; Shrikhande SV
    PET Clin; 2016 Jul; 11(3):233-41. PubMed ID: 27321028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT in Head-neck Malignancies: The Implications for Personalized Clinical Practice.
    Wassef HR; Hanna N; Colletti P
    PET Clin; 2016 Jul; 11(3):219-32. PubMed ID: 27321027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The scope and potentials of functional radionuclide imaging towards advancing personalized medicine in oncology: emphasis on PET-CT.
    Basu S
    Discov Med; 2012 Jan; 13(68):65-73. PubMed ID: 22284785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
    Basu B; Basu S
    Cancer Biother Radiopharm; 2016 Apr; 31(3):75-84. PubMed ID: 27093341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET Radiopharmaceuticals for Personalized Medicine.
    Sharma S
    Curr Drug Targets; 2016; 17(16):1894-1907. PubMed ID: 27440185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging requirements for personalized medicine: the oncologists point of view.
    Kruse V; Belle SV; Cocquyt V
    Curr Pharm Des; 2014; 20(14):2234-49. PubMed ID: 24025098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?
    Suresh Malapure S; Das KJ; Kumar R
    PET Clin; 2016 Jul; 11(3):297-303. PubMed ID: 27321033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of non-FDG-PET in the management of head and neck cancer.
    Heuveling DA; de Bree R; van Dongen GA
    Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tracers in oncology - preclinical and clinical evaluation].
    Krause BJ; Schwarzenböck S; Schwaiger M
    Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.
    Dimitrakopoulou-Strauss A
    Future Oncol; 2015; 11(7):1083-91. PubMed ID: 25804123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.
    Ayers EC; Fardin S; Gholami S; Alavi A; Mato AR
    PET Clin; 2016 Jul; 11(3):209-18. PubMed ID: 27321026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-FDG PET in the practice of oncology.
    Caroli P; Nanni C; Rubello D; Alavi A; Fanti S
    Indian J Cancer; 2010; 47(2):120-5. PubMed ID: 20448372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
    Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
    Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear Medicine Imaging Procedures in Oncology.
    Mohan AM; Beindorff N; Brenner W
    Methods Mol Biol; 2021; 2294():297-323. PubMed ID: 33742410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How We Read Oncologic FDG PET/CT.
    Hofman MS; Hicks RJ
    Cancer Imaging; 2016 Oct; 16(1):35. PubMed ID: 27756360
    [No Abstract]   [Full Text] [Related]  

  • 17. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in urologic oncology: positron emission tomography molecular imaging.
    Bouchelouche K; Oehr P
    Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron Emission Tomography in oncology: present and future of PET and PET/CT.
    Papathanassiou D; Bruna-Muraille C; Liehn JC; Nguyen TD; Curé H
    Crit Rev Oncol Hematol; 2009 Dec; 72(3):239-54. PubMed ID: 19091592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.